Beneficial effects of melatonin on acetylsalicylic acid induced liver damage in rats

M. Ediz Sarihan¹, Hakan Parlakpinar², Alaattin Polat³, Nigar Vardi⁴, Onural Ozhan², Ahmet Acet²

¹ Inonu University, Faculty of Medicine, Department of Emergency Medicine, Malatya, Turkey
² Inonu University, Faculty of Medicine, Department of Pharmacology, Malatya, Turkey
³ Inonu University, Faculty of Medicine, Department of Physiology, Malatya, Turkey
⁴ Inonu University, Faculty of Medicine, Department of Embryology and Histology, Malatya, Turkey

Received 06 Apr 2017; Accepted 17 Apr 2017
Available online 10.05.2017 with doi: 10.5455/medscience.2017.06.8628

Abstract
We investigated the effects of acute high doses of acetylsalicylic acid (ASA) on liver tissue and the protective and therapeutic effects of melatonin on ASA related damage. Forty rats were randomly divided into five groups of eight: group 1, control; group 2, administered 200 mg/kg ASA; group 3, administered 5 mg/kg melatonin 45 min before ASA; group 4, administered 5 mg/kg melatonin 45 min after ASA; group 5, administered 5 mg/kg melatonin. We measured malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced glutathione (GSH), myeloperoxidase (MPO), aspartate aminotransferase (AST) and alanine transaminase (ALT) in the liver. ASA treatment significantly increased MDA and MPO production, whereas it significantly decreased levels of SOD, CAT, GPx and GSH in the liver. Melatonin significantly decreased MDA and MPO production, whereas it caused increased levels of antioxidants. AST and ALT levels were higher after ASA treatment, whereas these levels were reduced significantly after melatonin administration. Our histopathological findings, including apoptosis, were consistent with the biochemical results. Melatonin exhibits beneficial effects against high dose ASA induced hepatotoxicity.

Keywords: Acetylsalicylic acid, liver, melatonin, oxidative stress, rat

Introduction
Acetylsalicylic acid (ASA) has been used as an analgesic, antipyretic and anti-inflammatory drug for many years [1]. ASA exerts these effects by inhibiting cyclo-oxygenase (COX), which blocks the pathway for prostaglandin synthesis from (arachidonic acid) [2,3]. ASA can block liver COX, which inhibits the synthesis of vasodilatory prostaglandins (PGs) in liver tissue and can cause deterioration of hepatic function [4]. ASA also increases oxidative stress, which causes toxicity and apoptosis [5-7].

The production of reactive oxygen species (ROS), depletion of cellular scavengers of ROS, arachidonic acid metabolism as a normal function, mitochondrial dysfunction and apoptosis have been reported to be the underlying causes for ASA induced hepatotoxicity [8]. Even low doses of ASA can cause lipid oxidation and impairment of defense mechanisms against oxidative injury [9,10]. The hepatotoxic side effects of ASA have been documented [11-13] One mechanism of this toxicity is believed to involve generation of ROS, which likely accounts for the pathophysiology of ASA induced hepatotoxicity. Free radicals can attack DNA, membrane lipids and proteins. Free radical damage may be responsible for degenerative process but lipid oxidation plays much more important role in tissue damage [14].

The main secretory product of the pineal gland, melatonin (N-acetyl-5-methoxytryptamine), exhibits free radical scavenging and antioxidant properties, and reduces neutrophil accumulation [15]. Melatonin also indirectly activates antioxidative enzyme productions, reduces lipid oxidation and regulates gene expression of several protective enzymes such as Cu/Zn superoxide dismutase (CuZn SOD) and Mn superoxide dismutase [16-18]. In addition, the metabolites of melatonin are even more effective antioxidants than melatonin during oxidative stress and inflammatory pathways [19,20]. Melatonin limits the oxidative breakdown of lipids and reduces oxidative damage both in vivo and in vitro [14].

The toxic effects of high dose ASA taken during therapy, by accident or in suicide attempts have been documented [1,9,10,21]. Our literature review revealed no studies concerning the protective and therapeutic effects of melatonin against ASA induced hepatotoxicity. We also investigated the acute effects of high doses of ASA on liver tissue. To do this, we investigated histopathological changes in the liver and biochemical alterations including...
changes in liver malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced glutathione (GSH), myeloperoxidase (MPO) aspartate aminotransferase (AST) and alanine transaminase (ALT) levels.

Materials and Methods

Animals and experimental design

Our experimental design followed ARRIVE (Animal in Research: Reporting in Vivo Experiments) guidelines [22]. Our study was approved by the Animal Ethics Committee and was conducted in accordance with the Animal Welfare Act and Guide for the Care and Use of Laboratory animals, Animal Ethics Committee” (NIH publication No. 5377-3, 1996).

Forty healthy 250−300 g Wistar albino male rats five months aged were obtained from the Inonu University Laboratory Animals Research Center and housed in a temperature (21 ± 2º C) and humidity (60 ± 5%) controlled room with a 12 h light:12 h dark cycle. The rats were fed standard commercial pellets and water ad libitum.

The rats were divided randomly into five groups of eight: group 1, untreated controls; group 2, 200 mg/kg ASA injected intraperitoneally (i.p.); group 3, 5 mg/kg melatonin injected i.p. 45 min before i.p. injection of 200 mg/kg ASA; group 4, 5 mg/kg melatonin injected i.p. 45 min after injection i.p. of 200 mg/kg ASA, and group 5, 5 mg/kg melatonin injected i.p. All drugs were administered as a single dose. The dosage of ASA and melatonin were selected based on previous dose-response studies [4,23,24]. ASA and melatonin were purchased from Sigma Chemical Co. (St. Louis, MO).

Four hours after ASA treatment, all rats were sacrificed using an overdose of 70 mg/kg ketamine plus 8 mg/kg xylazine. Firstly, blood was collected via vena cava inferior for AST and ALT analysis. Then, the liver was removed and one half was placed in formaldehyde solution for routine histopathological examination by light microscopy; the remaining half was placed in liquid nitrogen and stored at -70º C until assayed for MDA, MPO, SOD, CAT, GPx and GSH.

Biochemistry

Liver samples were homogenized in ice-cold phosphate buffered saline, pH 7.4. The homogenate was sonified with an ultrasonifier (Bronson sonifier 450) using three cycles of 20 sec sonications and 40 sec pause on ice, then centrifuged at 15,000 × g for 10 min at 4º C. Enzyme assays were performed immediately using the cell-free supernatant.

MDA content

MDA contents of the homogenates were assayed spectrophotometrically (UV-1601; Shimadzu, Kyoto, Japan) by measuring the presence of thiobarbituric acid reactive substances (TBARS) [19]. Three milliliters 1% phosphoric acid and 1 ml 0.6% thiobarbituric acid solution were added to 0.5 ml of plasma in a plastic tube. The mixture was heated in boiling water for 45 min. After the mixture cooled, the color was extracted into 4 ml n-butanol and the absorbance was measured at 532 nm. The amount of lipid peroxide was calculated as TBARS of lipid oxidation. The results were expressed as nmol/g tissue.

SOD activity

Total (Cu-Zn and Mn) SOD activity was assayed using the method of Sun et al. (2004). The method is based on the inhibition of nitroblue tetrazolium (NBT) reduction by the xanthine-xanthine oxidase system as a superoxide generator. SOD activity was expressed as U/g protein.

CAT activity

CAT activity was assayed using the method described by Aebi (1984). The assay is based on the determination of catalytic or peroxide activity of CAT. Results were expressed as K/g protein.

GPx activity

GPx activity was measured using the method described by Paglia and Valentine (1967). An enzymatic reaction in a glass plastic tube containing NADPH, GSH, sodium azide and glutathione reductase was initiated by adding H2O2 and the change in absorbance at 340 nm was monitored using a spectrophotometer. Results were expressed as U/g protein.

GSH content

GSH content was measured as nonprotein sulfhydryls in the liver tissue using the described method described by Uzbay et al. (2013). Aliquots of tissue homogenate were mixed with distilled water and 50% trichloroacetic acid in glass tubes and centrifuged at 3000 rpm for 15 min. The supernatants were mixed with 0.4 M Tris buffer, pH 8.9, and 0.01 M 5,5'-dithiobis (2-nitrobenzoic acid (DTNB) was added. After shaking the reaction mixture, the absorbance was measured against a blank with no homogenate at 412 nm within 5 min of the addition of DTNB. The absorbance values were extrapolated from a glutathione standard curve and expressed as µmol/g tissue.

MPO activity

MPO activity was determined using a 4-aminoantipyrine/phenol solution as the substrate for MPO-mediated oxidation by H2O2 and the change in absorbance at 510 nm was recorded [25]. One unit of MPO activity was defined as the amount that caused degradation of 1 µmol H2O2/min at 25º C. The results were expressed as U/g protein.
ALT and AST concentrations

We measured the plasma concentrations of the liver enzymes, ALT and AST, in serum samples of all groups of rats. The blood samples were centrifuged quickly to evaluate the serum levels of AST and ALT using an Olympus Autoanalyzer (Olympus Instruments, Tokyo, Japan). Activities were expressed as IU/L.

Histology

Liver tissue was fixed in 10% formalin and embedded in paraffin. The sections were stained with hematoxylin and eosin (H & E) and periodic acid-Schiff (PAS), and examined by observers blinded to the identities of the sections. We used the following criteria for liver damage: sinusoidal dilatation, congestion, intracytoplasmic vacuolization and necrotic changes including nuclear pyknosis or lysis, cytoplasmic alterations including absent cell boundaries, eosinophilia and cytoplasmic retraction. The degree of cellular alteration was scored semi-quantitatively as: 0, absent; 1, slight; 2, moderate; and 3, severe for each criterion. The overall tissue score was calculated as the sum of the scores for each criterion.

Immunohistochemistry

Five µm thick sections were mounted on pollysine coated slides for immunohistochemical analysis. A section of tonsil was used as positive control. After rehydrating through a graded series of alcohols, the samples were transferred to citrate buffer, pH 7.6, and heated in a microwave oven for 20 min. After cooling for 20 min at room temperature, the sections were washed with phosphate-buffered saline (PBS). The sections were placed in 0.3% H2O2 for 7 min, then washed with PBS. The sections were incubated with primary rabbit-polyclonal cysteine aspartate specific proteinase (caspase-3) (Neomarker, California) antibody for 30 min. The caspase-3 kit was used according to the manufacturer’s instructions with minor timing exceptions, then rinsed in PBS and incubated with biotinylated goat anti-polyvalent for 10 min and streptavidin peroxidase for 10 min at room temperature. Staining was completed with chromogen + substrate for 15 min, counterstained with Mayer’s hematoxylin for one min, rinsed in tap water and dehydrated. The sections were examined using a Leica DFC 280 light microscope (Leica Microsystems Imaging Solution Ltd., Cambridge, UK) by a histopathologist who was blinded to the origin of the sections. Caspase-3 positive cells were stained brown. Hepatocytes stained with caspase-3 were evaluated using Leica Q Win Image Analysis System. Caspase-3 stained cells were graded as: 0, none or a few stained hepatocytes; 1, stained hepatocytes < 25% of the sample; 2, stained hepatocytes 25–50% of the sample; 3, stained hepatocytes 50–75% of the sample; 4, stained hepatocytes > 75% of the sample.

Ten microscopic fields were analyzed using a 20 x objective for each specimen.

Statistical analysis

The sample sizes required for a power of 0.80 were estimated using NCSS software. All data were analyzed using a commercially available statistical software package (SPSS for Windows v. 22.0, Chicago, IL). Distributions of the groups were analyzed using the Kolmogorov-Smirnov test. Because all groups showed a normal distribution except for the number of hepatocytes stained with caspase-3, parametric statistical methods were used. After a significant Kruskal–Wallis H test, a Conover test also was performed for the histopathological results (Table 3). These histopathological results are given as medians (min–max). For other parameters, One-way ANOVA was performed with Tukey’s post-hoc test. Biochemical data are reported as means ± SD. Values for p ≤ 0.05 were considered statistically significant.

Results

All animals survived the experiment. There were no significant differences in the liver weights among the groups (data not shown).

Biochemistry

Effects of melatonin on serum parameters

The serum levels of AST and ALT were increased in rats given ASA compared to controls (132.17 ± 4.5 vs. 64.24 ± 2.1 and 102.05 ± 6.4 vs. 27.19 ± 2.4 U/l, respectively) (Table 1). AST and ALT levels were significantly decreased in the melatonin treated groups 3 and 4 compared to controls (70.34 ± 4.3 vs. 68.13 ± 2.8 and 35.29 ± 4.4 vs. 30.13 ± 5.8, respectively).

Effects of melatonin on antioxidant and oxidative stress status

Our findings are presented in Table 1. Briefly, production of both MDA and MPO in liver tissue was significantly greater than in controls in the ASA group, whereas SOD and CAT activities were significantly less than in the control group. Melatonin treatment both reduced the levels of MDA and MPO, and elevated SOD and CAT enzyme activities, significantly. Also, compared to the control group, ASA treatment caused significant reduction of both GPx and GSH levels in the liver tissue. Melatonin treatment significantly elevated GPx activity.

Histopathological analysis

Hepatocytes and sinusoids appeared normal in the control and melatonin groups, (Fig. 1A, B). PAS staining appeared where Kupffer cells were present (Fig. 1C, D). In the ASA group, the radial arrangement of hepatocytes from central
vein toward the periphery was deformed. Separated irregular areas consisting of necrotic hepatocytes were observed in the centrilobular region (Fig. 2A). In addition, vacuolization and increased eosinophilia was observed in the cytoplasm of some cells scattered randomly within areas with normal morphology (Fig. 2B). Eosinophilic cells, and shrinkage and darkened nuclei were increased in ASA group compared to controls. Fragmented hepatocytes were observed frequently around the central vein. Other conspicuous findings in ASA-treated group included sinusoidal dilation and congestion (Fig. 2C), and an increased number of Kupffer cell in this group compared to controls (8.1 ± 0.38) (Fig. 2D).

The architecture of the hepatocytes was altered less in the melatonin + ASA (group 3) and ASA + melatonin (group 4) groups, than in the ASA group. Most of the nuclei were euchromatic and shaped normally. Melatonin treatment did not ameliorate structural alterations completely, however. The mild degenerative alterations such as sinusoidal dilation were observed (Fig. 3A, B).

Cytoplasmic vacuolization and congestion were more prominent in the ASA + melatonin group (group 4) than in the melatonin + ASA group (group 3) (Fig. 3C, D). In both groups 3 and 4, melatonin treatment reduced the number of Kupffer cells significantly (Fig. 4A, B). The semiquantitative histological analysis and the number of Kupffer cell in the liver tissue are given in Table 2.

We found no caspase-3 immunostaining of the hepatocytes except for a few apoptotic cells in the control and melatonin groups (not shown). To the contrary, we observed that caspase-3 positive cells were increased significantly in the ASA group compared to controls (Fig. 5A). In group 4, melatonin treatment reduced the number of apoptotic cells significantly (Fig. 5B); however, prior to ASA treatment, melatonin did not prevent apoptosis immunoreactivity induced by ASA (Fig. 5C). The results of caspase-3 staining are given in Table 3.

### Table 1. Effects of melatonin on biochemical parameters

<table>
<thead>
<tr>
<th>Groups</th>
<th>MDA (nmol/g tissue)</th>
<th>CAT (K/g protein)</th>
<th>GPx (U/g tissue)</th>
<th>GSH (µ/g tissue)</th>
<th>MPO (U/g protein)</th>
<th>SOD (U/g protein)</th>
<th>AST (IU/L)</th>
<th>ALT (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>48.9 ± 14.9</td>
<td>38.3 ± 4.4</td>
<td>4.7 ± 1.3</td>
<td>2.6 ± 0.4</td>
<td>15.2 ± 4.7</td>
<td>34.3 ± 7.1</td>
<td>64.2 ± 2.1</td>
<td>27.2 ± 2.4</td>
</tr>
<tr>
<td>ASA</td>
<td>70.2 ± 12.6</td>
<td>18.2 ± 3.36</td>
<td>2.2 ± 0.5</td>
<td>1.7 ± 0.3</td>
<td>27.3 ± 6.2</td>
<td>22.1 ± 5.2</td>
<td>132.2 ± 4.5</td>
<td>102.1 ± 6.4</td>
</tr>
<tr>
<td>MEL + ASA</td>
<td>47.5 ± 12.9</td>
<td>26.2 ± 4.9</td>
<td>4.6 ± 0.4</td>
<td>2.4 ± 0.4</td>
<td>18.2 ± 3.4</td>
<td>32.3 ± 7.3</td>
<td>75.1 ± 3.2</td>
<td>31.5 ± 3.8</td>
</tr>
<tr>
<td>ASA + MEL</td>
<td>33.8 ± 5.5</td>
<td>27.1 ± 3.0</td>
<td>4.5 ± 0.4</td>
<td>2.4 ± 0.4</td>
<td>15.5 ± 3.3</td>
<td>31.8 ± 2.5</td>
<td>70.3 ± 4.3</td>
<td>35.3 ± 4.4</td>
</tr>
<tr>
<td>MEL</td>
<td>39.6 ± 14.3</td>
<td>36.9 ± 6.9</td>
<td>4.8 ± 1.1</td>
<td>2.3 ± 0.5</td>
<td>14.7 ± 1.5</td>
<td>37.3 ± 6.8</td>
<td>68.1 ± 2.8</td>
<td>30.1 ± 5.8</td>
</tr>
</tbody>
</table>

MEL, melatonin; ASA, acetylsalicylic acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
ap < 0.05 vs. control group; bp < 0.05 vs. ASA group.
### Table 2. Histological damage score and number of Kupffer Cells

<table>
<thead>
<tr>
<th>Groups</th>
<th>Congestion</th>
<th>Sinusoidal dilation</th>
<th>Vacuolization</th>
<th>Necrosis</th>
<th>Kupffer cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Control</td>
<td>0.1 ± 0.0</td>
<td>0.3 ± 0.2</td>
<td>0.2 ± 0.1</td>
<td>0.0 ± 0.0</td>
<td>4.1 ± 0.35</td>
</tr>
<tr>
<td>2. MEL</td>
<td>0.0 ± 0.0</td>
<td>0.1 ± 0.1</td>
<td>0.2 ± 0.1</td>
<td>0.0 ± 0.0</td>
<td>4.4 ± 0.28</td>
</tr>
<tr>
<td>3. ASA</td>
<td>1.2 ± 0.2</td>
<td>1.9 ± 0.2</td>
<td>0.7 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>8.1 ± 0.38</td>
</tr>
<tr>
<td>4. MEL + ASA</td>
<td>0.6 ± 0.2</td>
<td>1.0 ± 0.2</td>
<td>1.1 ± 0.4</td>
<td>0.4 ± 0.2</td>
<td>5.9 ± 0.40</td>
</tr>
<tr>
<td>5. ASA + MEL</td>
<td>0.2 ± 0.1</td>
<td>1.3 ± 0.2</td>
<td>0.2 ± 0.1</td>
<td>0.7 ± 0.3</td>
<td>5.7 ± 0.28</td>
</tr>
</tbody>
</table>

**p < 0.0001**

1) 3, 4

2) 3, 4

3) 1, 2, 4, 5

4) 1, 2, 3

5) 3

**p < 0.0001**

1) 3, 4, 5

2) 3, 4, 5

3) 1, 2, 4, 5

4) 1, 2, 3

5) 1, 2, 3

**p = 0.0001**

1) 3, 5

2) 3, 5

3) 1, 2, 4, 5

4) 3

5) 1, 2, 3

**p < 0.0001**

1) 3, 4, 5

2) 3, 4, 5

3) 1, 2, 4, 5

4) 1, 2, 3

5) 1, 2, 3

MEL, melatonin; ASA, acetylsalicylic acid.

### Table 3. Number of hepatocytes stained for caspase-3

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median (min-max)</th>
<th>p &lt; 0.0001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.5 (0.0 - 2.0)</td>
<td>3, 4, 5</td>
</tr>
<tr>
<td>MEL</td>
<td>0.0 (0.0 - 2.0)</td>
<td>3, 4, 5</td>
</tr>
<tr>
<td>ASA</td>
<td>3.0 (1.0 - 4.0)</td>
<td>1, 2, 4</td>
</tr>
<tr>
<td>ASA + MEL</td>
<td>2.0 (1.0 - 3.0)</td>
<td>1, 2, 3, 5</td>
</tr>
<tr>
<td>MEL + ASA</td>
<td>3.0 (1.0 - 4.0)</td>
<td>1, 2, 4</td>
</tr>
</tbody>
</table>

MEL, melatonin; ASA, acetylsalicylic acid.
Figure 1. Control (A, C) and MEL groups (B, D); The normal hepatocytes architecture and the central vein. Hepatocytes cords radiate from the central vein to the periphery of the lobule as the sinusoids, H-E X66. (C) and (D) Appearance of PAS-positive stained Kupffer cells (arrows) within sinusoidal lumen, PAS X132.

Figure 2. ASA group (A); Distruption of radial arrangement of hepatocytes is visible. Irregular area is comprised of hepatocytes with cell boundaries lost (arrows), H-E X66 (B) Hepatocytes with dense eosinophilic cytoplasm (arrows) and multiple intracytoplasmic vacuoles (arrow heads) are seen in centrilobular area, H-E X132. (C) Another striking finding is the presence of sinusoidal dilatation and congestion (stars), H-E X132. (D) An increase in the number of Kupffer cells is observed than control group (arrows), PAS X132.
Figure 3. ASA+melatonin (A) and Melatonin+ASA groups (B); Although the radial arrangement of hepatocytes is observed as relatively regular as moderate degenerative changes such as sinusoidal dilatation is still present in some area in both of groups (arrows), H-E X66. ASA+melatonin group (C); Intracytoplasmic vacuolisation (arrows) is evident (arrows), H-E X132. Melatonin+ASA group (D); Reduction in intracytoplasmic vacuolisation is observed according to ASA+melatonin group (arrows), H-E X132.

Figure 4. ASA+melatonin (A) and Melatonin+ASA groups (B); Reduction in the number of Kupffer cells is seen in melatonin treatment groups according to ASA group (arrows), PAS X132.
Discussion

We found that ASA treatment caused impairment of the antioxidant system in rat liver and that the deleterious effects of ASA could be detected by biochemical analysis and histopathology. Melatonin exhibited a preventive effect against the deleterious effects of ASA.

ROS possess a highly reactive unpaired electron that attacks biomolecules. The innate antioxidant system defends against oxidative stress. Deterioration of the balance between the rate of formation of ROS and antioxidant defenses causes cell injury by damaging membranes, DNA, protease activation, and lipid and protein oxidation, which culminate in apoptotic and necrotic cell death [26].

Viral infections, drug or alcohol toxicity, ischemia-reperfusion and drug induced hepatotoxicity among other factors can damage hepatocytes by causing oxidative stress and inflammation [23,27]. ASA is a commonly used drug and even at therapeutic doses can cause increased ROS and oxidative injury as evidenced by decreased levels of GPx, GSH and SOD, which together cause mitochondrial dysfunction [28,29].

We found that ASA caused increased production of MDA, which indicates the effects of oxidative stress on lipids, and MPO, which indicates inflammation owing to lipid oxidation. MPO participates in the generation of oxidants by neutrophils. ASA increases MDA levels even at low, otherwise nontoxic doses [10]. D'Argenio et al. [30] reported that ASA doubled gastric MDA production. MDA is a good indicator of the rate of lipid oxidation reported that minimal lipid oxidation levels in rat liver tissue are at 01:00 h, simultaneous with the peak time of melatonin synthesis [31,32]. GSH is an antioxidant that prevents ROS damage to cellular components. Consistent with above-mentioned biochemical these results, we reported earlier that administration of melatonin increased GSH levels significantly and reduced MDA production in the liver tissue of pinealectomized (PX) rats [14].

We found that administering melatonin before and after ASA treatment decreased MDA and MPO production compared to rats treated only with ASA. ASA treatment also decreased the levels of SOD, CAT, GPx and GSH significantly in the liver tissue. We found that melatonin ameliorated the content of these antioxidants to near normal levels. Our observations are consistent with earlier studies of melatonin effects on antioxidants [33-37]. We investigated earlier the protective and therapeutic effects of melatonin treatment against ASA induced kidney and testis damage [38]. We found that ASA increased MDA levels in both kidney and testis significantly, whereas it decreased the levels of SOD, CAT, GPx and GSH significantly in the kidney and CAT levels in testis. Melatonin significantly decreased MDA levels in the kidney and ameliorated the levels in the testis, whereas it elevated the levels of antioxidants.

Hepatotoxicity can be determined readily by liver function tests [39]. In the current study, we showed that melatonin treated group ameliorated the histological damage significantly. Our biochemical analyses and histopathological observations were consistent with each other.
We demonstrated the beneficial effect of melatonin on high-dose ASA induced liver injury. We found that ASA is a powerful oxidizing agent that caused significant oxidative damage to the rat liver tissue. According to our biochemical and histopathological results, melatonin exhibited protective effects against ASA induced hepatotoxicity by its antioxidant and free radical scavenging effects in rats. We believe that the antioxidant properties of melatonin could protect against the toxic effects of ASA on liver tissue and that it could be used to prevent liver injury caused by the use of high doses of ASA. Further experimental and clinical studies are required to confirm our findings before conducting clinical applications for treating ASA induced hepatotoxicity.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Acknowledgement

Sahabettin Kali and Berk Erdem were students in Bilim College involved in this study as an observer within the scope of the scientific and technological research council of Turkey student projects also Murat Akbalik involved in this study as a responsible teacher for college students after our ethical committee acceptance (Reference Number: 2012/A-02). We thank Bilim College for chemical support (caspase-3) which is used to histopathological analysis.

References

29. Raza H, John A, Benedet S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in...